INSP: Strong Fundamentals, but Only a B+ Score. What's Holding Inspire Medical Systems Back?

At first glance, it seems like a textbook case of a quality medtech company: a gross margin of 86.6%, almost negligible debt, and a QMA fundamental score of 91.2. Yet, the overall score for Inspire Medical Systems is only 63, a B+ — still decent, but significantly lower than the fundamentals alone would suggest.

The tension lies in the fact that the income statement numbers look stronger than the market behavior around the stock. After a sharp rebound in the recent period, the price is still 51% below the 52-week high, and some "big money" signals aren't as clear-cut as they might be for a company with such fundamentals.

Thesis

Inspire Medical Systems, Inc. (INSP) is, according to the provided data, a company with very strong fundamental quality but not a flawless market story. The QMA model gives the value pillar FVS 91.2 points, indicating an attractive combination of profitability, balance sheet, and valuation within the available data. However, the overall score is 63 because other layers of the picture are not as convincing.

The contrarian angle is simple: the fundamentals say "quality business," while the market and capital flow say "cautiously for now." It's not a clear case of a company being overlooked by the market, nor a stock with impeccable technicals and broad investor consensus. Rather, it's a company where strong operational performance meets skepticism after a previous decline and a not entirely smooth profile of quarterly numbers.

This is also contributed to by the difference between fundamentals and sentiment. The sentiment of NSS reports is 50, which is rather neutral. Insider activity IAS is only 28.3. The TSS technique scores 59 points, which is not weak, but neither is it a confirmation of a strong trend story. And although the smart-money pillar WHS reaches 68 points, the institutional picture is mixed: there are 279 reported institutions, but the change from the previous state is -33.

What the Numbers Say

The last reported period, Q4 as of 2025-12-31, shows revenues of $269.1 million and a year-over-year revenue growth of 12.2%. For a beginner, it's good to read it like this: the company is not growing explosively but is still expanding its business volume. In the medical device sector, growth is important because part of the costs is related to development, commercial infrastructure, and technology adoption by doctors and patients.

Even more striking are the margins. A gross margin of 86.6% means that after direct product costs, a very high share of each dollar of revenue remains for the company to cover research, sales, administration, and profit. An operating margin of 17.1% shows that the business is profitable after accounting for operating expenses. A net margin of 50.6% is extraordinarily high and appears in the data as the main reason why the fundamental score looks so strong.

However, caution is needed in interpretation here. The trend by quarters shows that the net margin was very variable: in Q1 2024 it was -6.1%, in Q2 2024 it was 5%, in Q3 2024 it was 9.1%, in Q4 2024 it was 14.7%. Then in Q1 2025, it fell to 1.5%, in Q2 2025 it was -1.6%, in Q3 2025 it was 4.4%, and in Q4 2025 it jumped to 50.6%. This is a big jump, and for an analytical view, it is crucial to monitor whether this is a new level of profitability or a one-time strong period.

Free cash flow was also not smooth. In Q1 2024, FCF was -$2.8 million, in Q2 2024 -$12.5 million, in Q3 2024 positive $44.3 million, and in Q4 2024 $62.2 million. In 2025, the pattern repeated unevenly: Q1 2025 -$15.1 million, Q2 2025 -$6.3 million, Q3 2025 $58.1 million. This suggests that the company can generate cash, but the quarterly course is volatile.

The balance sheet looks very healthy according to available data. Debt/Equity is 0.04, meaning debt relative to equity is low. Altman Z-Score 14.93 signals very strong financial health according to this type of model. Piotroski F-Score 7 out of 9 indicates solid fundamental quality across profitability, balance sheet, and operational trends.

Valuation is more mixed. A P/E of 14.5 looks moderate at first glance given the reported profitability, while a P/S of 7.35 indicates that the market still values each dollar of revenue quite highly. This is typical tension for medtech growth companies: a profitable year can optically cheapen the P/E, but the price-to-sales ratio still reminds that the market considers quality, margins, and potential future growth in the price.

The stock price has been strong recently: it rose by approximately 14.1% over about 30 days and by 54.2% over about 90 days. Yet, the last price of $70.5 is still 51% below the 52-week high. The twelve-month closing price range of $40.05–$143.99 shows that the market treats INSP as a high-volatility stock.

Bullish Scenario

The optimistic interpretation starts with the quality of the business. A gross margin of 86.6% is a strong signal that the product economy is very attractive. If the company can maintain revenue growth while also turning a high gross margin into more stable operating and net profitability, the fundamental picture can further improve.

The bullish scenario also relies on the fact that the last quarter showed significant profitability. A net profit of $136.1 million on revenues of $269.1 million is a very strong result. QMA catalysts/earnings score XS at 93 suggests that earnings dynamics or expectations around future reports are a significant positive element in the model.

Another supporting point is the balance sheet. Low debt Debt/Equity 0.04 gives the company flexibility. In an environment where some growth companies are facing higher capital costs, low debt is an advantage. Additionally, Altman Z-Score 14.93 supports the image of a financially stable company.

The model deviation from fair value is 14.6% positively. QMA does not say that the price development must follow the model, but it signals that according to its inputs, there is space between the current price and the model fair value. Third parties are also relatively constructive: the average target estimate of analysts is $135.73 from 28 analysts, implying a difference of 92.5% compared to the last price. At the same time, the overall rating of third parties is "Hold," so this element is not one-sidedly euphoric.

The trend in the number of shares can also be read positively: the data shows buybacks and a decreasing number of shares. If the company reduces the number of shares with a healthy balance sheet, it increases the significance of each remaining share in the overall business. However, it is important to monitor whether this trend continues without weakening financial flexibility.

Bearish Scenario

The pessimistic interpretation does not start with the company being fundamentally weak. It starts with the question of whether the last extremely strong net margin represents a sustainable reality. The jump from 4.4% in Q3 2025 to 50.6% in Q4 2025 is so significant that it deserves careful reading. If the next quarters return closer to earlier levels, the P/E of 14.5 might not look as comfortable optically.

The second weakness is the volatile FCF. The company had negative free cash flow in several quarters, including -$15.1 million in Q1 2025 and -$6.3 million in Q2 2025. Positive quarters like $58.1 million in Q3 2025 show the ability to generate cash, but volatility makes it difficult to draw a simple conclusion about cash flow stability.

The third element is market technique. TSS 59 and relative strength RS 71 are not bad values, especially after a strong 90-day move. Yet, the stock is still far below the 52-week high. This may mean that the market has not yet abandoned caution after the previous decline, or that some investors are using the rises to reduce exposure.

Institutional data is also mixed. Reported institutional positions are from quarterly reports published with a delay of about 45 days, so it is not a real-time picture. For the quarter ending 2026-06-30, 279 institutions were reported, but the change is -33. There were 71 new positions, 99 closed, 165 increased, and 77 decreased. This shows active interest but also a larger number of exits than new entries.

Insider activity is another drag on the overall score. Over approximately 90 days, public regulatory filings show purchases of $0 by 6 insiders and sales of $73.7 thousand by 3 insiders. The size of the sales is not significant according to these data, but the absence of purchases helps explain the low IAS 28.3.

What to Watch

The first practical metric is the net margin after Q4 2025. The level of 50.6% is a key reference point. If subsequent reports deviate significantly from this level towards earlier quarters, the market may begin to reassess how comfortable the current P/E of 14.5 is.

The second thing is the operating margin of 17.1%. It is less extreme than the net margin and can better show whether regular operational performance is improving. For a company with a gross margin of 86.6%, it is important how much of this gross economy actually flows into operating profit.

The third point is revenues against the last level of $269.1 million and year-over-year growth of 12.2%. It makes sense to monitor not only the growth itself but also whether higher revenues come with stable margins. Growth without improved cash flow would be a weaker signal than growth accompanied by positive FCF.

The fourth point is free cash flow. The last available value in the trend is $58.1 million for Q3 2025, while the previous two quarters of 2025 were negative. Practically, it is a question of whether positive FCF is becoming a more common state or whether the company continues to alternate strong and weak quarters.

The fifth point is institutional reports. For the next published quarter, it will be important to compare the number of institutions with the level of 279 and monitor the ratio of new and closed positions against the last picture of 71 new and 99 closed. Since these reports come with a delay of about 45 days, it is advisable to read them as a backward confirmation of the trend, not as a current signal of the day.

The sixth point is insider activity. After a period with purchases of $0 and sales of $73.7 thousand, any change in insider behavior would be relevant for the QMA picture, especially given the low IAS 28.3.

Risks

The biggest risk in the available data is the sustainability of profitability. The net margin of 50.6% in the last quarter is strong, but previous quarters were significantly lower and sometimes even negative. If the last result contained elements that will not be repeated, the fundamental view could be less favorable.

The second risk is cash flow volatility. Negative FCF in several quarters shows that quality margins do not automatically translate into cash every quarter. For investors monitoring financial stability, the difference between accounting profit and cash is crucial.

The third risk is related to valuation. A P/S of 7.35 is not a low multiple of sales. Thus, even despite the drop from the high, the market still values the company as a quality growth medical business. If revenue growth or margins disappoint, the room for revaluation can be significant.

The fourth risk is technical and psychological. The stock is still 51% below the 52-week high after a 90-day rise of 54.2%. This shows that the recent rebound has not yet erased the previous loss of confidence. In practice, such a stock can be sensitive to earnings reports, management comments, and changes in sector sentiment.

The fifth risk is mixed capital flow. Smart-money score 68 and institutional flow 65 are positive but not extreme. The decrease in the number of reported institutions by 33 and a higher number of closed than new positions show that part of the institutional market is not yet convinced.

How QMA Score Sees It

The QMA picture of INSP is uneven, and that's what makes it interesting. VALUE/FVS 91.2 is the main support of the entire analysis: strong margins, low debt, Piotroski F-Score 7, Altman Z-Score 14.93, and P/E 14.5 create a quality fundamental profile.

MOMENTUM/TSS 59, however, says that the technical picture is not as strong as the fundamental one. Relative strength 71 helps, but the 51% distance from the 52-week high reminds that the stock is still in the process of restoring confidence. SMART MONEY/WHS 68 and institutional flow 65 show a rather mildly positive than a clearly strong big money signal.

The quality of earnings EQS 70 supports the bullish interpretation, but volatile margins and FCF explain why the overall score is not closer to the fundamental pillar. The sentiment of NSS reports 50 is neutral, and insider activity IAS 28.3 is a clear weakness. Catalysts/earnings XS 93 are, on the other hand, very strong and suggest that further results may be important for the market story.

The overall score of 63 with a B+ grade does not say that INSP is a weak company. It rather says that the market does not yet fully trust the fundamentals. The data shows a quality medtech business with a very strong last quarter, but also with questions about the sustainability of margins, cash flow stability, insider activity, and institutional conviction.

This is an AUTOMATED ANALYTICAL and EDUCATIONAL consideration by QMA Brain, not an investment recommendation. Past performance and historical data do not guarantee future results. Find the stock detail here: open stock detail in QMA.